Daily Endocrinology Research Analysis
Analyzed 91 papers and selected 3 impactful papers.
Summary
Three high-impact studies advanced endocrinology today: a 53-cohort meta-analysis refines how femoral-neck BMD predicts fracture risk and supports updating FRAX; a multinational analysis shows shifting causes of death in diabetes with rising dementia and cancer prominence; and a human single-cell atlas of adipose vasculature reveals endothelial heterogeneity and EndMT-like states linked to obesity and type 2 diabetes.
Research Themes
- Risk prediction and guideline refinement in osteoporosis
- Evolving mortality patterns in diabetes (cardiometabolic and neurocognitive)
- Vascular remodeling and angiocrine dysfunction in obesity and T2D
Selected Articles
1. Predictive value of BMD for hip and other fractures: a meta-analysis to update FRAX.
In an individual-participant meta-analysis of 53 cohorts (n=307,205), femoral-neck BMD robustly predicted fractures, especially hip fractures, with age-dependent gradients of risk. Most hip fractures occurred among those with low bone mass/osteoporosis at baseline, supporting BMD-centric risk models and informing parameter updates for FRAX.
Impact: This IPD meta-analysis provides definitive, age- and sex-specific effect sizes for BMD-driven fracture risk that directly support recalibration of FRAX and clinical thresholds.
Clinical Implications: Clinicians should account for the attenuated hip fracture risk gradient with advancing age and the stability of MOF prediction when interpreting BMD. FRAX recalibration using these estimates may refine treatment thresholds across ages.
Key Findings
- At age 65, per SD decrease in femoral-neck BMD, hip fracture GR was 2.73 (men) and 2.61 (women).
- Hip fracture risk gradient declined with age (e.g., men: 3.49 at 50 years to 2.14 at 80 years).
- Most hip fractures occurred in participants with low bone mass/osteoporosis at baseline (men 73%, women 92%).
- MOF risk gradient was stable with age, unlike hip fractures.
- Time since measurement modestly attenuated hip fracture GR compared with age effects.
Methodological Strengths
- Individual-participant data meta-analysis across 53 predominantly population-based cohorts
- Large sample size (n=307,205) with sex-specific Poisson modeling and standardized risk gradients
Limitations
- Observational cohort data subject to residual confounding and measurement timing effects
- Generalizability may vary across regions/cohorts; DXA site limited to femoral neck in this analysis
Future Directions: Incorporate age-dependent gradients into FRAX recalibration, evaluate other BMD sites and microarchitectural metrics, and validate updated thresholds prospectively.
UNLABELLED: The relationship between bone mineral density (BMD) at the femoral neck and fracture risk was determined in a meta-analysis of primary data of 307205 men and women from 53 cohort studies. Low BMD was an important predictor of fracture risk, particularly for hip fracture. INTRODUCTION: This study aimed to quantify the relationship between DXA-measured femoral neck BMD and fracture risk and examine the effect of age, sex, time since measurement, and initial BMD value on fracture risk, with a view to updating FRAX®. METHODS: We studied 307,205 men and women from within 53 predominately population-based cohorts followed up for an average of 8.7 years and a total of 2,683,185 person-years. The association of BMD and fracture risk was examined using a Poisson model in each cohort separately by sex. Results were expressed as a gradient of risk (GR, hazard ratio/standard deviation decrease in BMD). The different studies were then merged using weighted coefficients. RESULTS: Most hip fractures arose in men and women with low bone mass or osteoporosis at baseline (73% and 92%, respectively) as was also the case for MOF (65% and 85%, respectively). BMD at the femoral neck strongly predicted hip fractures both in men and women with a similar gradient of risk and absolute risk at any given T-score. At the age of 65 years, the GR was 2.73 (95% CI = 2.29-3.26) in men and 2.61 (95% CI = 2.34-2.92) in women. However, the magnitude of association was significantly dependent on age, with a higher gradient of risk at younger ages. For example, at age 50 years, the GR was 3.49 (95% CI 2.51-4.84) in men and decreased to 2.14 (1.96-2.34) at age 80 years. The change in GR with age was slightly less marked in women (3.23 [2.75-3.80] and 2.11 [1.99-2.44], respectively). The GR for major osteoporotic fracture (MOF) remained unchanged with age (p = 0.12 for women and p = 0.89 for men). A significant decrease in GR for hip fracture was observed with increasing duration of follow-up, but the magnitude of the effect was modest compared with the effect of age. For other fracture outcomes, including non-hip major osteoporotic fracture, the gradient of risk was lower than for hip fracture. CONCLUSIONS: Femoral neck BMD is a risk factor for fracture of substantial importance, particularly for future hip fracture. The lower magnitude of association at older age is consistent with other non-skeletal factors contributing to hip fracture risk with advancing age. Its validation on an international basis supports its use in case finding strategies. Its use should, however, take account of the variations in predictive value of BMD with age, sex, length of follow-up, and BMD.
2. Trends in cause-specific mortality among people with and without diabetes in high-income settings: a multinational, population-based study.
Across 11 high-income jurisdictions over 1.7 billion person-years, cardiovascular and diabetes-related mortality declined in people with diabetes, while dementia mortality rose and cancer became the leading cause of death in four jurisdictions. Mortality rate ratios were largely stable, underscoring changing cause distributions rather than widening relative risks.
Impact: Reveals a major shift in causes of death in diabetes with policy implications—beyond cardioprotection to neurocognitive and cancer prevention strategies.
Clinical Implications: Care pathways for diabetes should integrate dementia risk reduction and cancer screening alongside cardiometabolic management, with health systems planning for rising neurocognitive burden.
Key Findings
- Cardiovascular mortality declined in people with diabetes in all jurisdictions (mean 5-year reduction 8.3% to 25.4%).
- Dementia mortality increased in people with and without diabetes in 6/7 jurisdictions analyzed for this outcome.
- By the end of follow-up, cancer was the leading cause of death in people with diabetes in 4/11 jurisdictions.
- Mortality rate ratios were generally stable; notable exception was a larger decline in CVD MRR in Lithuania.
- Diabetes-related mortality also declined in most jurisdictions.
Methodological Strengths
- Large, multinational, population-based administrative data with age- and sex-standardized Poisson modeling
- Longitudinal time series (2000–2023) enabling robust trend analyses across jurisdictions
Limitations
- Cause-of-death coding heterogeneity and potential misclassification across jurisdictions
- Aggregated data limit granularity (e.g., differentiation by diabetes type, treatment, and comorbidities)
Future Directions: Disaggregate trends by diabetes type and treatment era, evaluate drivers of rising dementia mortality, and test integrated screening/prevention strategies for cancer and cognitive decline.
BACKGROUND: Cardiovascular disease has historically been the most common cause of death (COD) among people with and without diabetes. However, substantial progress has been made in the management of cardiovascular disease. We conducted a multinational analysis to establish whether this trend is still the case. METHODS: In this multinational, population-based study, we assembled aggregated annual mortality data collected during routine clinical care from nationally or regionally representative administrative datasets in high-income jurisdictions between 2000 and 2023. For inclusion, datasets must have ongoing enrolment of new patients with diabetes, cause-specific death counts in people with and without diabetes, and sex-specific and age-specific data. We collected population size, counts of prevalent diabetes (type 1 and type 2), death counts, and person-years of follow-up in people with and without diagnosed diabetes by sex and 10-year age group. We estimated cause-specific trends in mortality rates, proportional mortality, and mortality rate ratios (MRR) for people with versus those without diabetes (type 1 and type 2) using Poisson models standardised for age and sex. FINDINGS: Using data from 11 jurisdictions, we identified 2·7 million deaths in people with diabetes and 11·0 million deaths in people without diabetes during a total of 1·7 billion person-years of follow-up. Cardiovascular disease mortality decreased in all jurisdictions in populations with and without diabetes. Mean 5-year declines in cardiovascular disease mortality among people with diabetes ranged from 8·3% (95% CI 5·9 to 10·7) to 25·4% (22·8 to 28·0). Mortality due to diabetes declined in most jurisdictions. Dementia mortality increased in people with and without diabetes in six (86%) of seven jurisdictions. Cancer mortality declined in people with diabetes in three (33%) of nine jurisdictions and in people without diabetes in six (67%). At the end of the observation period, cancer was the leading COD in people with diabetes in four (36%) of 11 jurisdictions. MRRs were generally stable for all CODs. Exceptions include Lithuania, where the mean 5-year change in MRR for cardiovascular disease was -7·6% (-10·1 to -5·1), indicating a more rapid fall in cardiovascular disease mortality in people with diabetes than in people without. For dementia, the MRR increased in Denmark (5-year change 8·0% [5·0 to 11·1]) and Scotland (11·4% [8·5 to 14·3]). INTERPRETATION: Mortality from cardiovascular disease and diabetes has declined among people with diabetes in most jurisdictions, whereas mortality from dementia has increased markedly, independent of age. Cardiovascular disease is no longer universally the most common COD among people with diabetes in high-income countries. FUNDING: US Centers for Disease Control and Prevention, Diabetes Australia Research Program, and Victoria State Government Operational Infrastructure Support Program.
3. Defining the vascular niche of human adipose tissue across metabolic states.
A human single-cell atlas of adipose vasculature across 65 donors reveals seven canonical endothelial subtypes and a distinct EndMT-like population with mixed endothelial, mesenchymal, adipocytic, and immune programs. Obesity and type 2 diabetes are associated with inflammatory and fibrotic vascular signatures, implicating endothelial remodeling in metabolic disease.
Impact: Provides a reference cellular atlas and mechanistic leads (EndMT-like states) linking vascular dysfunction to metabolic disease, opening avenues for endothelial-targeted therapies.
Clinical Implications: Identifies endothelial phenotypes and EndMT-like states that could serve as biomarkers or targets for vascular normalization strategies in obesity/T2D.
Key Findings
- Seven canonical endothelial cell subtypes were defined in human subcutaneous adipose tissue.
- A distinct EC population exhibited mixed endothelial, mesenchymal, adipocytic, and immune transcriptional features, consistent with EndMT-like states.
- Obesity and type 2 diabetes were associated with inflammatory and fibrotic vascular signatures.
- Whole-mount imaging and computational analyses supported the presence and organization of these EC states.
Methodological Strengths
- Large-scale single-cell RNA sequencing (~70,000 vascular cells) across 65 human donors
- Orthogonal validation with whole-mount imaging and integrative computational analyses
Limitations
- Cross-sectional human tissue analysis limits causal inference and temporal dynamics
- Focused on subcutaneous adipose tissue; depot- and sex-specific differences require further study
Future Directions: Longitudinal and interventional studies to test whether modulating EndMT-like states improves metabolic outcomes; expand to visceral depots and integrate spatial-omics.
Adipose tissue homeostasis depends on an intact vascular network that ensures adequate nutrient delivery and immune regulation. In obesity, vascular dysfunction, particularly within endothelial cells (ECs), contributes to inflammation and metabolic disease progression, yet the cellular organization of the human adipose vasculature remains poorly defined. Here we show, using single-cell RNA sequencing of nearly 70,000 vascular cells from human subcutaneous adipose tissue of 65 individuals, that the adipose vasculature is highly heterogeneous and consists of seven canonical EC subtypes. In addition, we identify a distinct population of ECs that display mixed endothelial, mesenchymal, adipocytic and immune transcriptional features. Computational analyses and whole-mount imaging support their presence and suggest that they emerge through endothelial-to-mesenchymal transition. Comparative analyses further reveal inflammatory and fibrotic vascular signatures in obesity and type 2 diabetes. Together, this atlas delineates the cellular complexity of the human adipose vasculature and highlights its contribution to metabolic disease.